{"title":"Beneficial Roles of Histone Deacetylase Inhibitor Butyrate to Multiple Myeloma, Acute Leukemia and Acute Myeloid Leukemia: Case Reports","authors":"A. Yagi, M. Hasegawa, H. Abe","doi":"10.17554/j.issn.2224-3992.2020.09.904","DOIUrl":null,"url":null,"abstract":"Multiple myeloma (MM) belongs to hematological malignancy that derives pro-survival/proliferative signals from the bone marrow niche, and its incidence is increasing worldwide. Butyrate, a well-known epigenetic histone deacetylase inhibitor, reduces the viability of MM cells, induces MM cell apoptosis via transcriptional activation of p21. Inpresent review we discuss butyrate as a potential therapeutic drug for MM and case reports of MM, acute leukemia, malignant lymphoma and glioma patients.","PeriodicalId":90217,"journal":{"name":"Journal of gastroenterology and hepatology research","volume":"9 1","pages":"3107-3112"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of gastroenterology and hepatology research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17554/j.issn.2224-3992.2020.09.904","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Multiple myeloma (MM) belongs to hematological malignancy that derives pro-survival/proliferative signals from the bone marrow niche, and its incidence is increasing worldwide. Butyrate, a well-known epigenetic histone deacetylase inhibitor, reduces the viability of MM cells, induces MM cell apoptosis via transcriptional activation of p21. Inpresent review we discuss butyrate as a potential therapeutic drug for MM and case reports of MM, acute leukemia, malignant lymphoma and glioma patients.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
